ClinicalTrials.gg
CompletedNCT04567524Updated Feb 8, 2023Results posted

A Multiple Dose Study to Assess the Safety, Tolerability and PK of Risperidone Extended Release Capsules

A Phase 2 interventional study of LYN-005 in Schizophrenia Schizoaffective, sponsored by Lyndra Inc.. Completed at 5 sites in United States. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Lyndra Inc. · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 758 studies in Psychotic Disorders with a site in United States — 96 open to participants now, 112 under way, 7 of them phase 3. Psychotic Disorders · United States.

Enrollment
476th of 681
34 · median 60
Started
2020
with 30 others
Phase 2
85 of 758
5 open now
Registered
596th of 758
by date

Among the 758 studies in Psychotic Disorders with a site in United States, this one is the 476th largest by enrollment of the 681 interventional ones that give a count, is one of 31 that started in 2020, is one of 85 in phase 2, and was the 596th registered.

Psychotic Disorders

1,589 studies on the registry are indexed under Psychotic Disorders; 281 are open to participants now.

Browse Psychotic Disorders studies →

Open to participants now

96 of the 758 studies in Psychotic Disorders with a site in United States are open now. Recruiting first, the newest first:

91 more — sign in →

All 96 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 204 Psychotic Disorders studies recruiting now, 53 (26%) set no upper age limit and 142 (70%) stop at 75 or younger; 50 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 758 studies in Psychotic Disorders with a site in United States, or all of them as a file.
02

Study summary

Lyndra is developing an oral, extended release (ER) formulation of risperidone (LYN-005) presented in a capsule dosage form with the intent of reducing the frequency of dosing orally-administered medications to once weekly or less and thereby improving the management of schizophrenia.

Study LYN-005-C-004 will evaluate the safety, tolerability, and pharmacokinetics (PK) of multiple dose administration of the ER formulation at two dose levels of LYN-005 relative to IR risperidone.

Read the detailed description

LYN-005-C-004 is a blinded, multiple-dose, randomized, parallel group, safety, tolerability and PK study of LYN-005 in subjects with a primary diagnosis of schizophrenia or schizoaffective disorder in general good health. Eligible subjects must be clinically stable and receiving a therapeutic dose of an approved oral antipsychotic drug for a minimum of 6 weeks at the time of Screening. Enrolled subjects will be evaluated under steady-state conditions on commercially-available IR risperidone tablets and then assigned in blinded fashion either to LYN-005 weekly or continued encapsulated IR risperidone daily for 3 weeks to attain (or continue) steady-state exposure.

03

Conditions studied

  • Schizophrenia Schizoaffective

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Eligibility for this study was met if each one of the following inclusion criteria was satisfied at Screening (or at baseline when specified):

  1. Male or female aged ≥18 and ≤50 years.
  2. Current diagnosis of schizophrenia or schizoaffective disorder according to criteria as confirmed by the MINI 7.0.2.
  3. The following psychiatric criteria were used to determine subject eligibility:

    1. Duration of diagnosis of schizophrenia or schizoaffective disorder of ≥2 years.
    2. Outpatient; not hospitalized for worsening of schizophrenia within the last 6 months (partial hospitalization for social management within this time period is acceptable).
    3. Medically stable over the last month and psychiatrically stable without significant symptom exacerbation over the last 3 months.
  4. Stabilized on an oral antipsychotic medication (single agent) for a minimum of 6 weeks at the time of Screening.
  5. On a stable dosage of all permitted non-antipsychotic medications (except for medication to be used on an as-needed basis) for at least 1 month prior to the Screening visit and for the duration of the study.
  6. CGI-S score of ≤4 (moderately ill).
  7. PANSS score of ≤80 points.
  8. (BMI) of ≥18 kg/m2 and ≤35 kg/m2.
  9. Able to read and understand study procedures and provide written before the initiation of any protocol-specific procedures.
  10. Willing to comply with all protocol-specified procedures and availability for the duration of the study.
  11. Subject has identified a caregiver or personal contact with whom the subject communicates with at least once a week.

Exclusion Criteria: Subject will not be considered eligible to participate in this study if any one of the following exclusion criteria is satisfied at Screening (or at baseline when specified):

  1. Subjects with known esophageal or GI disease, including but not limited to:

    1. Known strictures such as esophageal web, pyloric stenosis, or small intestinal stricture, or subjects with high risk of stricture, e.g., Crohn's disease.
    2. Diagnosis of a condition known to elevate or lower gastric pH, e.g., achlorhydria or hypochlorhydria.
    3. Prior varices or small or large bowel obstructions.
    4. Prior abdominal or upper gastrointestinal surgery (prior uncomplicated laparoscopic procedures including appendectomy or colectomy).
    5. History of dysphagia or aspiration in the last 5 years.
    6. History of an esophageal motility disorder or undergoing treatment for a gastric motility disorder.
    7. Significant history of diarrhea or constipation within 3 months of Screening
    8. Multiple episodes of abdominal pain within 3 months of Screening.
    9. Subjects who experience moderate or severe dysmenorrhea or menorrhagia (with use of pain medication) within 3 months of Screening.
    10. History of moderate to severe Acid Reflux Disease or a score of ≥2 on the Acid Reflux Severity Scale (ARSS) [2], indicating moderate to severe symptoms. The ARSS scale is as follows:

    None = 0 no symptoms Mild = 1 awareness of symptom, but easily tolerated Moderate = 2 discomfort sufficient to cause interference with normal activities Severe = 3 incapacitating, with inability to perform normal activities.

  2. Subjects with PILL-5 questionnaire score of 5 or greater.
  3. Medical history or current diagnoses indicating the presence of any of the below conditions:

    1. Presence of an uncontrolled, unstable, clinically significant medical condition could that could put the subject at risk because of participation in the study, interfere with the subject's ability to participate in the study or influence the interpretation of safety or PK evaluations.
    2. History of a major cardiovascular event (myocardial infarction, cardiac surgery or revascularization, unstable angina, stroke, or ) or a hospitalization for heart failure with 6 months of Screening.
    3. Any clinically significant illness, medical or surgical procedure or trauma within 4 weeks of Screening.
    4. Known status, including individuals who have undergone organ transplantation, on immunosuppression for an immunemediated disease, or are positive for (HIV).
    5. Subjects with a positive test for active or C at Screening. Subjects with successfully treated hepatitis B infection which has been resolved for greater than 1 year or successfully treated infection will not be excluded.
    6. Subjects who have donated more than 250 mL of blood within 30 days of Screening.
    7. Subjects who have difficulties with venipuncture/cannulation, including difficulty accessing veins for blood sampling and/or history of coagulopathy or endocarditis.
    8. Subjects with a current DSM-5 diagnosis of major depressive episode, panic disorder, agoraphobia, social anxiety disorder, obsessive- compulsive disorder, post-traumatic stress disorder, generalized anxiety disorder on the MINI 7.0.2 or in the judgment of the Investigator. (Note that individuals with depression secondary to schizoaffective disorder are eligible).
    9. Suicidal ideation associated with actual intent and a method or plan in the past 6 months, as measured by the C-SSRS (i.e., "Yes" answers on items 4 or 5) at Screening or having made a suicide attempt within the last 2 years.
    10. Known or suspected (non-febrile) seizure disorder.
    11. History of neuroleptic malignant syndrome.
    12. Current or history of clinically significant tardive dyskinesia.
    13. Known or suspected diagnosis of intellectual disability or organic brain disorder or other diagnosis that is primarily responsible for current symptoms and functional impairment.
    14. Medically non-adherent in the management of their schizophrenia/schizoaffective disorder.
  4. Use of the below medications/treatments in the 2 weeks before enrollment, including:

    1. Proton pump inhibitors or H2 blockers.
    2. Prokinetic agents.
    3. Medications that may interfere with the absorption, metabolism, or excretion of risperidone, e.g.:

      Drugs metabolized via pathway, such as macrolide antibiotics and azole antifungals). Moderate or strong CYP3A4 p-glycoprotein (P-gp) enzyme inducers and inhibitors (carbamazepine, phenytoin, rifampicin, phenobarbital, itraconazole, verapamil). Moderate or strong CYP2D6 inhibitors (e.g., fluoxetine, fluoxetine combinations, paroxetine), or quinidine.

    4. Concomitant medications, natural remedies, supplements or vitamins which are associated with changes to gastric motility or pH. Use of antacids is permissible, except within 2 hours of dosing with LYN-005.
    5. Benzodiazepines; except lorazepam, diazepam and oxazepam, which are acceptable if for the treatment of depression, anxiety or insomnia.
    6. Use of more than one antidepressant; or if on just one, a change in dose within 6 weeks of Screening.
    7. Depot antipsychotic use within 9 months of Screening.
    8. Electroconvulsive therapy within 3 months of Screening.
  5. Subjects with clinically significant abnormal safety (e.g. physical examination, vital sign) or safety laboratory assessments, specifically:

    1. Presence of a clinically significant abnormal laboratory result on blood or urine safety tests at Screening.
    2. Anemia ( below lower limit of normal reference range) at Screening.
    3. (ALT), aspartate aminotransferase (AST) ≥3.0 × (ULN), or total ≥1.5 × ULN.
    4. Moderate or severe renal insufficiency at Screening ( \<60 mL/min, as determined using the formula).
    5. Heart rate of \<50 beats per minute (bpm) at Screening.
    6. Systolic blood pressure ≤100 or ≥150 and/or diastolic blood pressure ≤60 mmgHg or ≥100 mmHg at Screening.
    7. ≥6.5% at Screening.
    8. Positive fecal occult blood test at Screening
    9. Clinically significant prolactin elevation (≥200 ng/mL for females; ≥100 ng/mL for males).
  6. Subjects with the below specified patterns of substance use at Screening:

    1. Fulfillment of the DSM-5 criteria for moderate or severe substance use disorder (excluding nicotine and caffeine) within 6 months of Screening.
    2. History of alcohol consumption exceeding moderate use; in males exceeding 21 units per week and in females exceeding 14 units per week (1 unit = 360 ml beer, 25 mL of 40% spirit or a 125 mL glass of wine) over the past month. Subjects are not permitted to consume alcohol during the inpatient stay nor 12 hours before any clinic visit while outpatient.
    3. Positive ethanol breathalyzer.
    4. Positive urine drug screen for substances of abuse other than cannabis.
    5. Heavy nicotine use (consumption of >40 cigarettes or >36 mg of nicotine from other sources [e.g., vaping products] daily) or daily use of smokeless tobacco.
  7. Subjects of who are (hetero) sexually active but unwilling to use acceptable means of through the EOS. For clarity, subjects who are at least 1 year are not of reproductive potential. Acceptable means of contraception include:

    1. Subjects who have been surgically sterilized.
    2. Females of reproductive potential: diaphragm, injectable, oral/patch contraceptives for a minimum of 6 weeks, contraceptive sponge, implant, or intrauterine device in use prior to enrollment.
    3. Males: condom in combination with any of the above means of contraception.
    4. All subjects: abstinence may be an acceptable means of contraception as long as the individual consents to initiate immediate use of double barrier protection for the duration of the study should (hetero) sexual intercourse occur.
  8. Subjects who are nursing or who have positive or indeterminate pregnancy tests at either Screening (serum test) or enrollment (urine test).
  9. Use of any experimental agent within 1 month or 5 half-lives of Screening, whichever is longer.
  10. Subjects who are employees or immediate family members of employees of the site, Sponsor or study-related vendors.
  11. History of a serious allergic or reaction to risperidone or LYN-005 (refer to Investigator's Brochure).
  12. Subjects with history of X-ray, computed tomography (CT) scan or angiogram of the abdomen within one year of Screening.
  13. Subjects with CYP2D6 poor or underdetermined metabolizer status based on genetic testing.
Terms in these criteria, in plain language(22)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Care provider)
Enrollment
34 participants (actual)

Study arms

  • Active comparator
    Arm 1

    LYN-005: capsules containing LYN-005 stellate; the 14mg dose of LYN-005 contains 3 active arms containing risperidone, and 3 inactive arms and the 28 mg dose of LYN-005 contains 6 active arms containing risperidone. AND IR Risperidone Matched Placebo: Orange capsule-shaped tablets containing inactive ingredient.

    Drug: LYN-005

  • Placebo comparator
    Arm 2

    LYN-005 Matched Placebo: Size 00EL capsules containing inactive ingredient with no stellate. AND IR Risperidone: Risperidone 2 mg (orange) capsule-shaped tablets.

    Drug: LYN-005

Interventions

  • DrugLYN-005

    LYN-005 (14 or 28 mg weekly) plus IR risperidone matched placebo.

    Also known as: Risperidone

06

What researchers measure

Primary outcomes

  1. Participants With at Least One Treatment Emergent Adverse Event (TEAE).

    Incidence of treatment emergent adverse events (TEAEs) reported as participants with at least one treatment emergent adverse event (TEAE).

    Time frame: 35 days

  2. Total Number of Treatment Emergent Adverse Events (TEAEs).

    Incidence of treatment emergent adverse events (TEAEs) reported as total number of TEAEs.

    Time frame: 35 days

  3. Active Moiety PK (Cmax)

    Active moiety Cmax (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 Extended Release (ER) capsules relative to Immediate Release (IR) risperidone tablets at 2 dose levels.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

  4. Active Moiety PK (AUC0-24, AUC0-168)

    Active moiety AUC (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

  5. Active Moiety Tmax

    Active Moiety Tmax (h) (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

Secondary outcomes

  1. PK of Risperidone (Cmax).

    To characterize exposure (Cmax) of risperidone during the switch to LYN-005.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

  2. PK of Risperidone (AUC0-24h, AUC0-168).

    To characterize exposure (AUC0-24h, AUC0-168) of risperidone during the switch to LYN-005.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

  3. PK of 9-Hydroxyrisperidone (Cmax).

    To characterize exposure (Cmax) of 9-Hydroxyrisperidone during the switch to LYN-005.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

  4. PK of 9-Hydroxyrisperidone (AUC0-24h, AUC0-168h).

    To characterize exposure (AUC0-24h, AUC0-168h) of 9-Hydroxyrisperidone during the switch to LYN-005.

    Time frame: Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.

07

Results

Posted Feb 8, 2023

Participant flow

This study was conducted at 5 sites that randomized participants in the US. The study period was 13 August 2020 (first signed informed consent) to 22 December 2020 (last participant visit/observation)

Participant flow — Overall Study
MilestoneLYN-005 14mgLYN-005 28mgRisperidone 2 mgRisperidone 4 mg
Started121244
Completed91143
Not completed3101
Withdrew: Adverse event1100
Withdrew: Withdrawal by subject2001

Outcome measures

PrimaryParticipants With at Least One Treatment Emergent Adverse Event (TEAE).

Incidence of treatment emergent adverse events (TEAEs) reported as participants with at least one treatment emergent adverse event (TEAE).

Time frame:
35 days
Reported as:
Number · Number of Participants with TEAEs
Participants With at Least One Treatment Emergent Adverse Event (TEAE).
Number of Participants with TEAEsLYN-005 14mgLYN-005 28mgOverall LYN-005Risperidone 2 mgRisperidone 4 mgOverall Risperidone
Participants With at Least One Treatment Emergent Adverse Event (TEAE).10818112
PrimaryTotal Number of Treatment Emergent Adverse Events (TEAEs).

Incidence of treatment emergent adverse events (TEAEs) reported as total number of TEAEs.

Time frame:
35 days
Reported as:
Number · Number of Experienced TEAEs
Total Number of Treatment Emergent Adverse Events (TEAEs).
Number of Experienced TEAEsLYN-005 14mgLYN-005 28mgOverall LYN-005Risperidone 2 mgRisperidone 4 mgOverall Risperidone
Total Number of Treatment Emergent Adverse Events (TEAEs).152136224
PrimaryActive Moiety PK (Cmax)

Active moiety Cmax (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 Extended Release (ER) capsules relative to Immediate Release (IR) risperidone tablets at 2 dose levels.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · ng/mL
Active Moiety PK (Cmax)
ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
Active Moiety PK (Cmax)31.0 ± 37.520.0 ± 56.718.6 ± 42.924.8 ± 38.330.3 ± 17.531.2 ± 68.724.6 ± 405.731.2 ± 32.130.4 ± 102.754.1 ± 19.346.3 ± 23.848.8 ± 40.9
PrimaryActive Moiety PK (AUC0-24, AUC0-168)

Active moiety AUC (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · h*ng/mL
Active Moiety PK (AUC0-24, AUC0-168)
h*ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
AUC0-24377 ± 44.0361 ± 49.0371 ± 47.4301 ± 23.1326 ± 19.1359 ± 32.6472 ± 137.7575 ± 39.3568 ± 104.3732 ± 46.3753 ± 44.9687 ± 36.9
AUC0-168—1820 ± 52.12120 ± 53.2————3350 ± 42.32950 ± 121.1———
PrimaryActive Moiety Tmax

Active Moiety Tmax (h) (risperidone and 9-hydroxyrisperidone combined) after repeat weekly doses of LYN-005 ER capsules relative to IR risperidone tablets at 2 dose levels.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · hours
Active Moiety Tmax
hoursLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
Active Moiety Tmax1.9 (0.0 to 4.0)23.7 (4.0 to 120.0)23.8 (0.0 to 72.0)3.0 (1.0 to 4.0)1.5 (1.0 to 2.0)3.0 (2.0 to 4.0)1.0 (0.6 to 7.9)24.1 (6.1 to 72.5)23.8 (0.0 to 169.0)2.1 (0.8 to 6.0)4.0 (1.1 to 6.1)2.0 (2.0 to 2.1)
SecondaryPK of Risperidone (Cmax).

To characterize exposure (Cmax) of risperidone during the switch to LYN-005.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · ng/mL
PK of Risperidone (Cmax).
ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
PK of Risperidone (Cmax).11.7 ± 58.24.44 ± 95.34.07 ± 59.19.97 ± 111.012.3 ± 40.515.6 ± 84.221.2 ± 55.66.87 ± 72.77.39 ± 230.917.0 ± 21.213.5 ± 32.614.0 ± 33.0
SecondaryPK of Risperidone (AUC0-24h, AUC0-168).

To characterize exposure (AUC0-24h, AUC0-168) of risperidone during the switch to LYN-005.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · h*ng/mL
PK of Risperidone (AUC0-24h, AUC0-168).
h*ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
AUC0-24h54.9 ± 81.565.8 ± 93.365.2 ± 66.643.4 ± 131.247.7 ± 103.586.2 ± 58.1113 ± 109.9111 ± 88.1119 ± 257.487.1 ± 67.282.4 ± 67.084.4 ± 80.5
AUC0-168—227 ± 87.3306 ± 67.1————806 ± 91.2453 ± 276.8———
SecondaryPK of 9-Hydroxyrisperidone (Cmax).

To characterize exposure (Cmax) of 9-Hydroxyrisperidone during the switch to LYN-005.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · ng/mL
PK of 9-Hydroxyrisperidone (Cmax).
ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
PK of 9-Hydroxyrisperidone (Cmax).20.8 ± 31.016.1 ± 49.615.6 ± 41.915.5 ± 12.117.5 ± 37.816.9 ± 53.316.0 ± 282.324.7 ± 26.022.5 ± 91.139.6 ± 22.935.7 ± 24.536.2 ± 38.4
SecondaryPK of 9-Hydroxyrisperidone (AUC0-24h, AUC0-168h).

To characterize exposure (AUC0-24h, AUC0-168h) of 9-Hydroxyrisperidone during the switch to LYN-005.

Time frame:
Reported data was obtained following multiple dose administration of 3 weekly doses [(IR, Day-1), (ER, Week 1), ER Week 3)] of 14 or 28 mg risperidone LYN-005 capsules to assess extended release PK.
Reported as:
Geometric mean · h*ng/mL
PK of 9-Hydroxyrisperidone (AUC0-24h, AUC0-168h).
h*ng/mLLYN-005 14 mg (A)LYN-005 14 mg (B)LYN-005 14 mg (C)Risperidone 2 mg (A)Risperidone 2 mg (B)Risperidone 2 mg (C)LYN-005 28 mg (A)LYN-005 28 mg (B)LYN-005 28 mg (C)Risperidone 4 mg (A)Risperidone 4 mg (B)Risperidone 4 mg (C)
AUC0-24h315 ± 39.7268 ± 38.2302 ± 47.0243 ± 11.2262 ± 20.8265 ± 26.6268 ± 272.6441 ± 33.6523 ± 177.9641 ± 43.5665 ± 42.9645 ± 45.5
AUC0-168h—1530 ± 51.71770 ± 54.4————2720 ± 35.92090 ± 100.5———

Adverse events

Collected over 35 days Double-blind Period consisted of the period between Day 1 to Day 35.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LYN-005 14 mg0/12 (0%)0/12 (0%)10/12 (83.3%)
LYN-005 28 mg0/12 (0%)0/12 (0%)8/12 (66.7%)
IR Risperidone 2 mg0/4 (0%)0/4 (0%)1/4 (25%)
IR Risperidone 4 mg0/4 (0%)0/4 (0%)1/4 (25%)
Most frequent other events
Showing 10 of 22
Most frequent other events
EventLYN-005 14 mgLYN-005 28 mgIR Risperidone 2 mgIR Risperidone 4 mg
NauseaGastrointestinal disorders2/123/120/40/4
Abdominal PainGastrointestinal disorders1/123/120/40/4
DiarrhoeaGastrointestinal disorders0/120/120/41/4
Alanine Aminotransferase IncreasedInvestigations1/120/121/40/4
Weight IncreasedInvestigations0/121/121/40/4
AkathisiaNervous system disorders0/120/120/41/4
Abdominal Pain UpperGastrointestinal disorders2/121/120/40/4
Abdominal DiscomfortGastrointestinal disorders0/122/120/40/4
VomitingGastrointestinal disorders0/122/120/40/4
HeadacheNervous system disorders1/122/120/40/4

Baseline characteristics

Age, Continuous
Age, Continuous(years)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Mean36.0 ± 6.2434.3 ± 7.4635.0 ± 7.1243.5 ± 7.8536.2 ± 7.28
Sex: Female, Male
Sex: Female, Male(Participants)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Female23106
Male1093426
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Race — Black or African American11114430
Race — White11002
Body Mass Index (BMI)
Body Mass Index (BMI)(kg/m^2)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Mean29.57 ± 4.69524.98 ± 4.47626.48 ± 2.68026.78 ± 6.08627.11 ± 4.835
ESRS Total Score at Baseline
ESRS Total Score at Baseline(units on a scale)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Mean0.2 ± 0.580.6 ± 2.020 ± 00.8 ± 1.50.4 ± 1.36
CGI-S Total Score at Baseline
CGI-S Total Score at Baseline(units on a scale)LYN-005 14 mgLYN-005 28 mgRisperidone 2 mgRisperidone 4 mgTotal
Mean2.9 ± 0.513.0 ± 0.852.8 ± 0.503.3 ± 0.503.0 ± 0.65
08

Study locations

5 sites
  • Collaborative Neuroscience Research, LLC
    Long Beach, California 90806, United States
  • Atlanta Center for Medical Research
    Atlanta, Georgia 30331, United States
  • Hassman Research Institute
    Marlton, New Jersey 08053, United States
  • Community Clinical Research, Inc
    Austin, Texas 78754, United States
  • Pillar Clinical Research, LLC
    Richardson, Texas 75080, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2020 to primary completion in Dec 2020, 4 months.

Results were first posted in Feb 2023, 2 years 1 month after primary completion.

Of 39 phase 2 interventional studies under Psychotic Disorders, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 4 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2020
First posted
Sep 28, 2020
StartActual
Aug 13, 2020
Primary completionActual
Dec 22, 2020
CompletionActual
Dec 22, 2020
Results first posted
Feb 8, 2023
Last update
Feb 8, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04567524
Lead sponsor
Lyndra Inc.
Collaborators
Worldwide Clinical Trials
Responsible party
Sponsor
First posted
Sep 28, 2020
Start date
Aug 13, 2020
Primary completion
Dec 22, 2020
Completion
Dec 22, 2020
Results posted
Feb 8, 2023
Last update
Feb 8, 2023

Study contacts

Richard Scranton, MD, MPH
principal investigator · Chief Medical Officer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion